Olaratumab for soft tissue sarcoma

References

• Fletcher CDM, Hogendoorn PCW, Mertens F, et al. WHO classification of tumours of soft tissue and bone. pathology and genetics of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
   Google Scholar
• Savina M, Le Cesne A, Blay JY. Patterns of care and outcome of patients (pts) with metastatic soft-tissue sarcoma (STS) according to histological subtype and treatment setting: the METASTARC study. BMC Med. Forthcoming 2017.
   PubMed Web of Science ®Google Scholar
• Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–711. DOI:10.1056/NEJMra041866
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol. 1975;1:63–76.
   PubMedGoogle Scholar
• Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4:103–112.
   PubMedGoogle Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–423.
   PubMed Web of Science ®Google Scholar
• Seddon BM, Whelan J, Strauss SJ, et al. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl; abstr 10500).
   PubMed Web of Science ®Google Scholar
• Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without Palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016;34:3898–3905.
   PubMed Web of Science ®Google Scholar
• Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247–274.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–1316.
   PubMed Web of Science ®Google Scholar
• Seifert RA, Hart CE, Phillips PE, et al. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem. 1989;264:8771–8778.
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjöblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3:439–443.
   PubMed Web of Science ®Google Scholar
• Shah GD, Loizos N, Youssoufian H, et al. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α. Cancer. 2010;116:1018–1026.
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006;81:1241–1257.
   PubMed Web of Science ®Google Scholar
• Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 2004;23:2800–2810. DOI:10.1038/sj.emboj.7600289
   PubMed Web of Science ®Google Scholar
• Fleming TP, Matsui T, Aaronson SA. Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Exp Gerontol. 1992;27:523–532.
   PubMed Web of Science ®Google Scholar
• Dewaele B, Floris G, Finalet-Ferreiro J, et al. Coactivated platelet-derived growth factor receptor α and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res. 2010;70:7304–7314.
   PubMed Web of Science ®Google Scholar
• Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008;27:6550–6560. DOI:10.1038/onc.2008.255
   PubMed Web of Science ®Google Scholar
• Adams SF, Hickson JA, Hutto JY, et al. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007;104:524–528.
   PubMed Web of Science ®Google Scholar
• Ho AL, Vasudeva SD, Laé M, et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012;72:4515–4525.
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357–5364. DOI:10.1200/JCO.2005.14.068
   PubMed Web of Science ®Google Scholar
• Ramos AH, Dutt A, Mermel C, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009;8:2042–2050.
   PubMed Web of Science ®Google Scholar
• Fitzer-Attas CJ, Do MS, Feigelson S, et al. Modification of PDGFalpha receptor expression or function alters the metastatic phenotype of 3LL cells. Oncogene. 1997;15:1545–1554.
   PubMed Web of Science ®Google Scholar
• Dolloff NG, Shulby SS, Nelson AV, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor. Oncogene. 2005;24:6848–6854.
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjöblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–5484.
   PubMed Web of Science ®Google Scholar
• Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005;4:369–379.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Sweeney C, Youssoufian H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73(3):595604.
   Web of Science ®Google Scholar
• Doi T, Ma Y, Dontabhaktuni A. et al. Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Sci. 2014;105(7):862.
   PubMed Web of Science ®Google Scholar
• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–497.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145.
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–2021. DOI:10.1158/1535-7163.MCT-07-0193
   PubMed Web of Science ®Google Scholar
• Savina M, Litière S, Penel N, et al. Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: a meta-analysis. J Clin Oncol. 2015;33(suppl; abstr 10547).
   Google Scholar
• Zer A, Prince RM, Amir E, et al. Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: end point selection, surrogacy, and quality of reporting. J Clin Oncol. 2016;34:1469–1475.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–1637.
   PubMed Web of Science ®Google Scholar
• Chudley L, McCann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother. 2012;61:2161–2170.
   PubMed Web of Science ®Google Scholar
• Liang C, Li L, Fraser CD, et al. The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer. 2015;29:1019.
   Web of Science ®Google Scholar
• Teng CL, Wang CY, Chen YH, et al. Optimal sequence of Irinotecan and Oxaliplatin-based regimens in metastatic colorectal cancer: a population-based observational study. Plos One. 2015;10:e0135673. DOI:10.1371/journal.pone.0135673
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205–214.
   PubMed Web of Science ®Google Scholar